Farmas USA

ACAD

Sorpresón o nos andan engañando como tontos

ACADIA Pharmaceuticals Announces Positive Top-Line Results From Phase II Study of Pimavanserin for Alzheimer’s Disease Psychosis
Data Support Moving Forward With Further Development in Alzheimer’s Disease Psychosis
http://ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-newsArticle&ID=2230818

"Que las ventas de Nuplazid serán una mierda", zas! Casi el doble de ventas de las estimadas. "Que el estudio de ADP tiene un 75% de fail", zas! Aprobado.

En fin, enhorabuena a Investing que creo que es el único que se quedó comprado a este evento.

Inicia PM en 40 pavos! +53%

ACAD
Ahora está en +25. A ver si da oportunidad de entrar pero sobre 30/31 creo que puede ser buena entrada.

PSTI

Pluristem and Sosei CVC to establish a new corporation for the commercialization of PLX-PAD in Japan
Sosei Corporate Venture Capital (Sosei CVC) and Pluristem Therapeutics (NASDAQ:PSTI) announces the signing of an agreement for the establishment of a new Japanese corporation (NewCo) for the clinical development and commercialization of Pluristem’s PLX-PAD cell therapy product in Japan.
Pluristem will own 35% of NewCo in return for its contribution of a perpetual license to commercialize PLX-PAD for Critical Limb Ischemia (CLI) in Japan. All proprietary rights related to PLX-PAD will be exclusively owned by Pluristem. Sosei CVC’s investment fund, Sosei RMF1, together with additional Japanese investors will raise and invest ~$11M (~ ‎¥‎1.3 billion) in return for ownership of 65% of NewCo.
Japan’s regulatory agency has already agreed on the study design of a 75-patient clinical trial in CLI for potential conditional marketing approval under an accelerated pathway.
http://seekingalpha.com/news/3231632-pluristem-sosei-cvc-establish-new-corporation-commercialization-plx-pad-japan

CLVS

Por cierto, dejé ayer una orden en CLVS y estoy dentro a 42,27 y llevo ya el culo...

ACAD

Cuidado, que parece que por Twitter no gustan mucho:

spins a pimvanserin failure to look positive, says @AF_biotech. Shape-shifting ph2 tend to do that

"Positive" but not the proper primary endpoint. 12weeks vs 6weeks was one of the reasons we were on the sidelines

this is not a signal finding trial , we know Pima affects hallucinations, point is can it sustain it at 12 weeks in ADP? No, ergo fail

https://endpts.com/acadia-shares-soar-as-nuplazid-clears-mid-stage-hurdle-for-alzheimers-psychosis/

ACAD
Gracias Ana, lo acabo de leer. Y bajando en PM desde la euforia inicial. Mejor nos quedamos quietos y vemos como se desarrolla la sesión.

CLVS

Las noticias parecen cojonudas sin embargo. Ayer me tragué la conferencia de prensa también y está todo en orden.

http://www.fool.com/investing/2016/12/19/surprise-clovis-oncology-nabs-early-ok.aspx

ACAD

Yo le pongo orden a 27,10